Fresenius SE Share Holder Equity 2016-2024 | FSNUY
Fresenius SE share holder equity from 2016 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
- Fresenius SE share holder equity for the quarter ending June 30, 2024 was $21.110B, a 38.4% decline year-over-year.
- Fresenius SE share holder equity for 2023 was $21.268B, a 37.34% decline from 2022.
- Fresenius SE share holder equity for 2022 was $33.945B, a 2.04% decline from 2021.
- Fresenius SE share holder equity for 2021 was $34.651B, a 16.57% increase from 2020.
Fresenius SE Annual Share Holder Equity
(Millions of US $) |
| 2023 |
$21,268 |
| 2022 |
$33,945 |
| 2021 |
$34,651 |
| 2020 |
$29,726 |
| 2019 |
$29,770 |
| 2018 |
$18,200 |
| 2017 |
$24,550 |
| 2016 |
$22,597 |
| 2015 |
$19,991 |
Fresenius SE Quarterly Share Holder Equity
(Millions of US $) |
| 2024-06-30 |
$21,110 |
| 2024-03-31 |
$21,840 |
| 2023-12-31 |
$21,268 |
| 2023-09-30 |
$32,959 |
| 2023-06-30 |
$34,271 |
| 2023-03-31 |
$34,535 |
| 2022-12-31 |
$33,945 |
| 2022-09-30 |
$34,402 |
| 2022-06-30 |
$34,090 |
| 2022-03-31 |
$34,321 |
| 2021-12-31 |
$34,651 |
| 2021-09-30 |
$33,237 |
| 2021-06-30 |
$32,690 |
| 2021-03-31 |
$33,171 |
| 2020-12-31 |
$29,726 |
| 2020-09-30 |
$30,629 |
| 2020-06-30 |
$30,007 |
| 2020-03-31 |
$29,738 |
| 2019-12-31 |
$29,770 |
| 2019-09-30 |
$29,686 |
| 2019-06-30 |
$28,529 |
| 2019-03-31 |
$29,338 |
| 2018-12-31 |
$18,200 |
| 2018-09-30 |
$17,227 |
| 2018-06-30 |
$17,151 |
| 2018-03-31 |
$17,066 |
| 2017-12-31 |
$24,550 |
| 2017-09-30 |
$24,878 |
| 2017-06-30 |
$23,120 |
| 2017-03-31 |
$23,361 |
| 2016-12-31 |
$22,597 |
| 2016-09-30 |
$21,121 |
| 2016-06-30 |
$20,850 |
| 2016-03-31 |
$19,868 |
| 2015-12-31 |
$19,991 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$20.921B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
